Anticancer Bioscience engages selectively in partnerships centered on the clinical development of product candidates and related diagnostic tools. As the company enters the clinical stage, collaboration is limited to activities that directly inform clinical development decisions.
Partnership discussions are considered primarily after completion of Phase 1a, when initial safety, pharmacokinetic, and mechanistic data are available to support downstream development.
Current areas of engagement include:
Licensing of clinical-stage drug candidates following Phase 1a
Clinical development collaborations, including Phase 1b and Phase 2 studies
Combination therapy development involving our products and approved or investigational agents
Companion or complementary diagnostic development aligned with ongoing clinical studies
For partnership discussions consistent with this scope and timing, please contact us.